Ault Global Holdings Inc. (NYSEAMERICAN: DPW) has announced the appointment of Christopher K. Wu as the new Alternative Investments Executive Vice President and Ault Alliance Inc. President and will report to William B. Horne, the company’s CEO.
Ault appoints Ault Alliance president.
Milton “Todd” Ault III, Ault Global Executive Chairman, said that Chris has more than 20 years of experience in financial restructuring, investment banking, and principal investment and will be an excellent addition to the company. He added that they are looking forward to Chris’s impact with investment sourcing, business development, strategic planning, and growing shareholder value.
Wu said, “I am excited to join Ault Global Holdings and I am looking forward to creating significant shareholder value from Ault Global’s investment platform by finding undervalued and disruptive investment opportunities as well as optimizing financing and growth for its operating businesses.”
Verastem Oncology appoints two new Board directors
Verastem Oncology (NASDAQ: VSTM) dropped 2.71% after the company announced Lesley Solomon and Paul Bunn’s appointment to the Board of directors. Bunn is a renowned oncologist who has been vital in identifying new diagnostics and treatment strategies to improve cancer patients’ outcomes. On the other hand, Lesley, a Venture Chair at Redesign Health, has extensive leadership and expertise in creating long-term revenue growth for several early-stage health and life sciences startups.
Verastem Oncology lead director of the Board, Michael Kauffman, said that Bunn, who has had an exceptional career in oncology and combined with Lesley’s track record and experience in unmet needs identification in health would be a massive addition to the company’s Board. He said that he is welcoming Bunn and Lesley at a time when Verastem Oncology is building on its recent success after FDA’s Breakthrough Therapy designation grant for VS-6766 combination with defactinib.